Merrill Lynch Pharma/Biotech & Medical Device Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
Exact Sciences driving PreGen-Plus adoption: Grassroots effort by the firm is under way to get its fecal DNA colorectal cancer screening test included in the American Cancer Society's cancer detection guidelines to help drive adoption. The test recorded about $4.9 mil. in 2004 sales. Exact Sciences also has applied for Medicare inclusion and expects a decision within about nine months, President & CEO Don Hardison said during a Feb. 10 presentation at the Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference in New York. PreGen-Plus was shown to be four times more effective in identifying invasive cancers than Beckman Coulter's market-leading Hemoccult II fecal occult blood test in a recent study in the New England Journal of Medicine (1"The Gray Sheet" Jan. 3, 2005, p. 18)...
You may also be interested in...
Cook Zilver goes global
Paclitaxel-eluting peripheral stent safety and efficacy to be studied in 760-patient, 50-site trial in Europe, Asia, Australia and Canada. Enrollment for a 60-patient pilot trial, which could be converted to a pivotal study to support a PMA for the Zilver PTX stent for femoropopliteal arteries above the knee, is ongoing in the U.S. (1"The Gray Sheet" Feb. 14, 2005, p. 27)...
Cook Zilver goes global
Paclitaxel-eluting peripheral stent safety and efficacy to be studied in 760-patient, 50-site trial in Europe, Asia, Australia and Canada. Enrollment for a 60-patient pilot trial, which could be converted to a pivotal study to support a PMA for the Zilver PTX stent for femoropopliteal arteries above the knee, is ongoing in the U.S. (1"The Gray Sheet" Feb. 14, 2005, p. 27)...
Angiotech Looks Beyond Stents To Other Anti-Scarring Treatments
Angiotech will begin studies evaluating paclitaxel for elbow and knee injuries in an effort to diversify its product offerings starting in the third quarter